Our immunotherapy portfolio* is designed to recognize and kill highly-expressed multiple tumor targets. With more than 20 years of R&D in different immune therapies to treat blood cancer and solid tumors, GIMI has a broad and extensive portfolio of target approaches for CAR-T therapy, Engineered Immune Effector (EIE) therapy, and Dendritic Cell (DC) vaccines.
In clinical studies, our immune therapy products have shown high safety and efficacy, contributing to durable anti-tumor responses.
Our immunotherapy portfolio has been applied to over 1000 patients in different clinical trials through collaborations with different hospitals targeting both hematological malignancies and solid tumors.
In a 2018 article published in Nature Reviews Drug Discovery by Dr. Jun Tang and colleagues, the global landscape of immuno-oncology research was summarized. The study highlighted 655 institutions worldwide that were engaged in related research, with four of the top 15 institutions being research organizations—three from China. The highest-ranked institution listed is ShenZhen Geno-immune Medical Institute.
According to 2022 statistics from BioClub, the United States leads in immune cell therapy development with 1,336 active projects, followed by China (498 projects), South Korea (141), the UK (138), and Japan (136). Among corporate and institutional rankings, the ShenZhen Geno-immune Medical Institute topped the list domestically.
